Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups

This multicenter prospective phase 2 trial analyzed disease-free survival (DFS) in myelofibrosis patients receiving ruxolitinib for 6 months before transplantation. Seventy-six patients were recruited. Age-adjusted dynamic international prognostic scoring system was intermediate-1, intermediate-2, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Robin, Marie, Porcher, Raphael, Orvain, Corentin, Bay, Jacques-Olivier, Barraco, Fiorenza, Huynh, Anne, Charbonnier, Amandine, Forcade, Edouard, Chantepie, Sylvain, Bulabois, Claude, Yakoub-Agha, Ibrahim, Detrait, Marie, Michonneau, David, Turlure, Pascal, Raus, Nicole, Boyer, Françoise, Suarez, Felipe, Vincent, Laure, Guyen, Stéphanie N., Cornillon, Jérôme, Villate, Alban, Dupriez, Brigitte, Cassinat, Bruno, Rolland, Valérie, Schlageter, Marie Hélène, Socié, Gérard, Kiladjian, Jean-Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992510/
https://www.ncbi.nlm.nih.gov/pubmed/33767402
http://dx.doi.org/10.1038/s41409-021-01252-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992510/
https://www.ncbi.nlm.nih.gov/pubmed/33767402
http://dx.doi.org/10.1038/s41409-021-01252-7

Ejemplares similares